Company intelligence / Profile preview

Engimmune Therapeutics

Ownership: Private
Development stage: Preclinical

Overview

Engimmune has not yet reported clinical results. Its lead asset ENGI‑003 is in preclinical development targeting liver cancer with a planned first-in-human trial in 2026. The pipeline includes several other preclinical programs focused on solid tumors using engineered soluble TCR modalities.

Therapeutic areas: Oncology
Modalities: Soluble T-cell receptor (TCR) engagersTCR-T cell therapiesSoluble TCR biologics (sTCRs)Recombinant fusion proteins
Industry: Biotech

Drug pipeline

4 assets

ENGI-003

Preclinical

3 more assets in the full pipeline.

Request access →

Partnerships

No major pharma partnerships disclosed as of May 2025. Investors include BaseLaunch and ETH Zurich as supporters/collaborators.

Beyond the preview

Go deeper on Engimmune Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Engimmune Therapeutics.

Explore the full profile